Association Between Oral Microbiome and Esophageal Diseases: A State-of-the-art Review
Bernard R, Fazili I, Rajagopala SV, Das SR, Hiremath G

ISSN: 0257-2753 (Print), eISSN: 1421-9875 (Online)
https://www.karger.com/DDI
Digestive Diseases

Disclaimer:
Accepted, unedited article not yet assigned to an issue. The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publisher and the editor(s). The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to the content.

Copyright:
© S. Karger AG, Basel
Association Between Oral Microbiome and Esophageal Diseases: A State-of-the-art Review

Rachel Bernard, DO\(^a\), Irtiqa Fazili\(^b\), Seesandra V. Rajagopala, PhD\(^c\), Suman R. Das, PhD\(^d\), Girish Hiremath, MD MPH\(^a\)

\(^a\)Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Monroe Carrell Jr Vanderbilt Children’s Hospital, Nashville, Tennessee, USA
\(^b\)University of Tennessee Health Science Center, Memphis, Tennessee, USA
\(^c\)Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA
\(^d\)Department of Otolaryngology and Department of Pathology Microbiology and Immunology, Vanderbilt University Medical Center, Tennessee, USA

Short Title: Oral Microbiome and Esophageal Diseases

Corresponding Author:
Girish Hiremath, MD, MPH
Division of Pediatric Gastroenterology, Hepatology, and Nutrition
Monroe Carrell Jr Vanderbilt Children’s Hospital
2200 Children’s Way, Suite 11226 Doctors’ Office Tower, Nashville, TN, 38201
Tel: 615-322-7449
E-mail: Girish.Hiremath@vumc.org

Number of Tables: 1
Number of Figures: 2
Word count: Abstract: 202; Body text: 3,565

Keywords: Human microbiome, Esophageal diseases, Esophageal neoplasms, Gastrointestinal microbiome, Barrett Esophagus

ABSTRACT
Background: Esophageal conditions result in significant morbidity and mortality worldwide. There is growing enthusiasm for discerning the role of microbiome in esophageal diseases. Conceivably, the focus has been on examining the role of local microbiome in esophageal diseases although this is somewhat limited by the invasive approach required to sample the esophageal tissue. Given the ease of sampling the oral cavity combined with the advances in genomic techniques, there is immense interest in discovering the role of the oral microbiome in esophageal conditions.

Summary: In this review, we aim to discuss the current evidence highlighting the association between the oral microbiome and esophageal diseases. In particular, we have focused on summarizing the alterations in oral microbiome associated with malignant, pre-malignant, and benign esophageal cancers, inflammatory and infectious conditions, and esophageal dysmotility diseases. Identifying alterations in the oral microbiome is key to advancing our understanding of the etiopathogenesis and progression of esophageal diseases, promoting novel diagnostics, and laying the foundation for personalized treatment approaches.
**Key Messages:** Further studies are needed to unravel the mechanisms by which the oral microbiome influences the development and progression of esophageal diseases, as well as to investigate whether alterations in the oral microbiome can impact the natural history of various esophageal diseases.

**Keywords:** Human microbiome, Esophageal diseases, Esophageal neoplasms, Gastrointestinal microbiome, Barrett Esophagus

**INTRODUCTION**

In the United States alone, it is estimated that 18,440 new cases of esophageal cancer will be diagnosed in 2020 and 16,170 deaths are expected from the disease [1]. Likewise, the incidence, prevalence, and the health care burden related to the benign esophageal disorders such as eosinophilic esophagitis (EoE) and gastroesophageal reflux disease (GERD) have significantly increased within the past two decades, particularly in the western hemisphere [2, 3]. At present, histologic examination of esophageal samples obtained via endoscopy remains the mainstay of diagnosing esophageal pathology. However, this approach is invasive, burdensome, and expensive. As such, there is an crucial need to identify and develop newer and efficient approaches to advance diagnostics as well as to improve our understanding of the pathobiology of esophageal diseases to ultimately improve clinical outcomes.

While pathogenesis of most the esophageal diseases remains to be fully delineated, the etiological studies have focused on the interaction between hereditary probability, environmental factors, the host immune regulation, and the commensal microbiome. In the recent years, there has been growing interest in uncovering the role of the microbiome in esophageal diseases. These efforts have been accelerated by the advances in genomic techniques. These technological developments have allowed us to simultaneously explore numerous pieces of the microbial microenvironment including microbial make up and function as well as to infer community function [4]. For instance, the use of next-generation sequencing (NGS) technology has helped to illuminate the genetic variations and the interconnection between the host and pathogen [5, 6]. The local dysbiosis has been well studied in esophageal disorders [7, 8]. Emerging evidence suggests that the inherent esophageal microbiome is comparable to the oral microbiome but with key taxonomic differences [9–11]. While the association between oral microbiome and oral, oropharyngeal, and gastrointestinal cancers has been previously published, the association between alterations in the oral microbiome and esophageal diseases has not been reviewed [12–14].

The human oral microbiota, defined as all the microorganisms that are found on or in the human oral cavity and its contiguous extensions (stopping at the distal esophagus), have been well studied [15]. The oral cavity has over 775 bacterial species [16] and its composition is suspected to be affected by many variables including host genetics [17], geography [18], age [19], oral health [20], lifestyle habits [21], social factors [22], and medications [23]. Studies investigating the composition of the oral microbiota in healthy individuals have demonstrated a predominance of gram-positive organisms including Abiotrophia, Peptostreptococcus, Streptococcus, Stomatococcus, Actinomyces, Bifidobacterium, Corynebacterium, Eubacterium, Lactobacillus, Propionibacterium, Pseudoramibacter, and Rothia [16]. Gram-negative organisms colonized in the healthy oral microbiome include Moraxella, Neisseria, Veillonella, Campylobacter, Capnocytophaga, Desulfoabacter, Desulfovibrio, Eikenella, Fusobacterium, Hemophilus, Leptotrichia, Prevotella, Seleniumas, Simonsiella, Treponema, and Wolinella [16]. In this narrative review, we aimed to summarize the literature describing the associations between alterations in the oral microbiome and esophageal diseases in humans.

**METHODS**

**Search strategy**

To identify relevant studies, we searched publications in PubMed, Google Scholar, and Web of Science corresponding to the ‘PEO’ format (population = human, exposure = oral microbiome, outcome = esophageal diseases) which is recommended for a narrative review [24]. In order to optimize the search for relevant publications, no date limits were imposed. A combination of search terms such as oral microbiome (or microbiota), human oral microbiome (or microbiota), salivary microbiome (or microbiota), oral bacteria, oral bacterial diversity, microbiome (or microbiota) of the oropharynx, oral swabs, and esophageal (or oesophageal) diseases, esophageal (or oesophageal) malignancies or cancers [including adenocarcinoma (EAC), squamous cell carcinoma (ESCC)], Barrett’s esophagus (BE), eosinophilic esophagitis (EoE), gastroesophageal diseases (GERD),
reflux esophagitis (or oesophagitis), esophageal (or oesophageal) infections (due to candidiasis, herpes virus, and cytomegalovirus), esophageal (or oesophageal) achalasia, and megaesophagus (or megaoesophagus) were used.

**Inclusion and Exclusion criteria**

We included publications which reported changes in the oral microbiome in adult and pediatric patients with the esophageal diseases listed above. To ensure quality, non-original articles, non-human studies, and abstract-only publications were excluded. Additionally, studies that focused on the esophageal microbiome alone, compared the esophageal microbiome with changes in the microbiome at other sites other than the oral microbiome, or those published in languages other than English were also excluded.

**Data extraction**

Two authors (I.F., R.B.) evaluated articles for eligibility and quality, and abstracted data independently according to the guidelines [25]. A standardized data extraction form was designed to collect: title, author, publication year, country of origin, study type, specific aims, research methods and conclusions. Statistical outcomes related to the average species diversity (alpha diversity, Chao1 or ACE index, Mantel test), the extent of change in community composition (beta diversity, Shannon diversity index, Simpson diversity index), percentage of relative abundance, number of operational taxonomic units (OTUs), and Area Under the Receiver Operating Characteristic (AUROC) were extracted when available. Any disagreement between authors in data abstraction was resolved by discussion with the senior author (G.H.) and review of the publication(s). This approach allowed for minimization of the risk of bias.

**RESULTS**

**Study selection**

Forty-six publications were identified. Of these, 28 publications were discarded after reviewing their title and abstracts, and 18 full articles were assessed for eligibility. Of these, 16 articles were included in the narrative review and qualitative synthesis (Fig. 1). Our major findings are summarized in Table 1 and Figure 2.

**Oral Microbiome in Esophageal malignancies:**

Narikiyo et al. for the first time reported specific oral bacteria associated with esophageal malignancy [26]. By cloning the 16S rRNA gene amplicons into a shuttle vector then sequencing the 16S amplicon clones to identify representative bacterial taxon, they analyzed saliva collected from Japanese subjects with uncategorized esophageal carcinoma and healthy controls. They found that *Treponema denticola* (45%) and *Streptococcus anginosus* (12%), were abundant in saliva collected from esophageal cancer patients and were absent in the healthy controls. Subsequently, they analyzed esophageal cancer tissue samples collected from subjects living in other countries and found similar results suggesting the abundance of salivary *T. denticola* and *S. anginosus* in subjects with esophageal cancer was not unique to Japanese patients. Recently, Kageyama et al. conducted a case-control study examining the salivary microbiota in patients with different gastrointestinal tract cancers, including 12 with unspecified esophageal cancer and their age- and sex-matched controls [27]. The operational taxonomic units (OTUs) corresponding to *Porphyromonas gingivalis* (estimated relative abundance: 0.3% vs 0.0%, p<0.01), *Corynebacterium* species (0.5% vs 0.1% relative abundance, p <0.01), and *Fusobacterium nucleatum subspecies vincentii* (0.45% vs. 0.1%, p<0.05) were more abundant in the saliva of esophageal cancer patients compared to that of the healthy controls. Additionally, 16S rRNA gene sequencing of the saliva samples demonstrated a significantly higher salivary bacterial diversity in esophageal cancer patients than healthy controls (number of OTUs, P= 0.02; Shannon Index, p< 0.01; Chao1, p= 0.04). Zhao et al. also recently evaluated alterations of the oral microbiota in 39 uncategorized esophageal cancer patients and 51 healthy volunteers via mouth rinses [28]. 16S rRNA sequencing revealed the differential abundance of several species between the two groups. The esophageal cancer group demonstrated increased *Firmicutes*, *Negativicutes*, *Selenomonadales, Prevotellaceae, Prevotella*, and *Veillonellaceae* taxa. Conversely, *Proteobacteria, Betaproteobacterina, Neisseriales, Neisseriaceae*, and *Neisseria* taxa were decreased. However, there was no significant difference in alpha diversity between the esophageal cancer and healthy control group (Shannon, p=0.2; Simpson, p=0.071).

In 2015, X. Chen et al. focused on oral microbiome associations with ESCC [29]. In this study, fasting saliva samples were collected from 87 incident and histopathologically confirmed ESCC patients, 63 subjects with dysplasia, and 85 healthy controls. Using 16S rRNA gene sequencing, they observed a higher relative abundance of *Streptococcus* (percent abundance 21.9% vs 16.1%, p<0.01), *Prevotella* (42.4% vs 36.1%,...
Interestingly, predominance of gram associated microbiome, the uvular swabs, which reflected the oral microbiome composition, showed a higher abundance of Proteobacteria microbiome in BE patients had high relative abundance of Firmicutes (27.1% vs 14.6%; p=0.005) and decreased abundance of Proteobacteria (23.8% vs 34.5%; p=0.02). When comparing patients with BE to controls, the results demonstrated a relative abundance of Lautropia, Streptococcus, and a genus in the order Bacteroidales, which the authors suggest could be used to precisely identify BE with high sensitivity (96.9%) and specificity (88.2%) (AUROC of 0.94; 95% CI: 0.885-1.00; p=0.04 vs Lautropia alone). However, they did not observe any differences in the average species diversity (alpha diversity) when comparing patients with BE to controls (mean Shannon index: BE 2.73 vs controls 2.89; p=0.10). In another study, Okereke et al. obtained samples from the esophagus (distal, middle, proximal, BE) as well as collected swabs from the uvula and the endoscope in 17 patients with BE [36]. While the study compared the different techniques (i.e. uvula swab vs endoscope swab vs tissue biopsy) and their associated microbiome, the uvular swabs, which reflected the oral microbiome composition, showed a predominance of gram-negative organisms. In particular, 16S rRNA sequencing demonstrated Fusobacterium (estimated 30%), Prevotella (30%), and Dialister (15%) had the highest relative proportions in patients with BE. Interestingly, Streptococcus (5%) was detected, but in a lesser quantity.

**Benign Esophageal Diseases:**

*Porphyromonas* (8.9% vs 6.5%, p<0.01) in the ESCC patients when compared to the non-ESCC patients (including subjects with dysplasia and healthy controls). The ESCC patients also had decreased carriage of *Lautropia, Bulleidia, Cantonella, Corynebacterium, Morrella, Peptococcus* and *Cardiobacterium*. Furthermore, ESCC patients had an overall lower or comparable relative abundance of most of the other genera and decreased microbial diversity compared to those with esophageal dysplasia or healthy controls (p<0.001). Likewise, Q. Wang et al. also utilized 16S rRNA sequencing to investigate saliva samples collected from 20 patients with ESCC and 21 healthy controls [30]. They found that the ESCC patients had a higher proportion of Firmicutes (estimated relative abundance: 50.0% vs 40.4%), *Bacillus* (0.30% vs 0.20%), *Lactobacillus* (0.25% vs 0.20%) and a decreased abundance of *Gammaproteobacteria* (0.25% vs 0.30%) compared to the healthy controls. The diversity and richness in the ESCC samples tended to be lower than those of the healthy control group but these differences did not achieve statistical significance (ACE, Chao1, Shannon index, Simpson index all p>0.05). In addition, M.F. Chen et al. recently used 16S rRNA sequencing to investigate the esophageal microbiome from oral biofilms obtained from 34 patients with ESCC and 18 healthy donors by swabbing the dental plaque at the gingival margin on the molars with sterilized toothpicks [31]. Results showed the alpha and beta diversity differed amongst ESCC and healthy donors. Specifically, *Streptococcus species*, *Veillonella parvula*, and *P. gingivalis* were more abundant in the oral biofilms of ESCC patients than in those of healthy volunteers. Similarly, Meng et al. evaluated saliva samples from 30 ESCC patients together with 22 healthy controls [32]. 16S rRNA sequencing results showed that *Porphyromonas* (p=0.001), *Streptococcus* (p=0.01), and *Leptotrichia* (p=0.009) were the most abundantly enriched in the ESCC saliva.

In a case control study, Peters et al. took the investigation of the oral microbiome in esophageal cancers a step further by including ESCC and EAC patient [33]. Using 16S rRNA gene sequencing, they compared mouthwash samples from 25 ESCC patients to 50 matched controls, and 81 EAC patients to 160 matched controls. They found that the abundance of the periodontal pathogen *Porphyromonas gingivalis* trended with higher risk of ESCC [Odds Ratio (OR) 95% confidence interval (95% CI) = 1.30 [0.96–1.77], p=0.09]. Additionally, the abundance of the periodontal pathogen, *Tannerella forsythia*, was positively associated with the risk of EAC (relative risk (RR) 95% CI): 1.21 [1.01–1.46], p=0.04) and depletion of the commensal genus *Neisseria* and the species *Streptococcus pneumoniae* were associated with lower risk of EAC (all p<0.05). Alpha and beta diversity did not differ significantly from matched controls in the EAC or ESCC cases. Additionally, Kawasaki et al. investigated subgingival dental plaques and unstimulated saliva from 61 patients with esophageal cancer (58 with ESCC and 3 with EAC) and 62 cancer free age matched individuals [34]. Using bacteria gDNA and real-time PCR to calculate the bacterial copy numbers for six pre-selected bacterial species, the saliva samples demonstrated an increased prevalence (p<10^-3) and number of copies of *Aggregatibacter actinomycetemcomitans* in the esophageal cancer patients compared to the control patients (p=0.001). *S. anginosus* was also significantly increased in the esophageal cancer patients (p= 0.004).

**Oral Microbiome in Pre-Malignant Esophageal Diseases:**

Two recent studies have examined the composition of the oral microbiome in BE. In one study, Snider et al. collected saliva samples from a total of 49 patients prior to their endoscopy of whom 32 had BE and 17 were controls [35]. 16S rRNA gene sequencing of these saliva samples revealed that at the phylum level the oral microbiome in BE patients had high relative abundance of Firmicutes (27.1% vs 14.6%; p=0.005) and decreased abundance of Proteobacteria (23.8% vs 34.5%; p=0.02). When comparing patients with BE to controls, the results demonstrated a relative abundance of Lautropia, Streptococcus, and a genus in the order Bacteroidales, which the authors suggest could be used to precisely identify BE with high sensitivity (96.9%) and specificity (88.2%) (AUROC of 0.94; 95% CI: 0.885-1.00; p=0.04 vs Lautropia alone). However, they did not observe any differences in the average species diversity (alpha diversity) when comparing patients with BE to controls (mean Shannon index: BE 2.73 vs controls 2.89; p=0.10). In another study, Okereke et al. obtained samples from the esophagus (distal, middle, proximal, BE) as well as collected swabs from the uvula and the endoscope in 17 patients with BE [36]. While the study compared the different techniques (i.e. uvula swab vs endoscope swab vs tissue biopsy) and their associated microbiome, the uvular swabs, which reflected the oral microbiome composition, showed a predominance of gram-negative organisms. In particular, 16S rRNA sequencing demonstrated Fusobacterium (estimated 30%), Prevotella (30%), and Dialister (15%) had the highest relative proportions in patients with BE. Interestingly, Streptococcus (5%) was detected, but in a lesser quantity.
Benitez et al. was the first group to study the oral and esophageal microbiota in EoE [37]. In their study involving children, they used 16S rRNA gene sequencing to compare contents of the oral swabs and esophageal biopsies collected from 35 non-EoE controls and 33 EoE patients. Of the 33 children with EoE, 18 had active EoE (defined as ≥15 eosinophils per high power field (hpf) per the 2011 consensus recommendations) [38] and 15 had inactive EoE (defined as <15 eosinophils per hpf). Although this study focused on the esophageal microbiota and its comparison to the oral microbiota, the study established that both oral and esophageal environments were predominantly composed of *Streptococcus*, *Neisseria*, and *Prevotella* (Mantel correlation= 0.16, p value: 0.008; Procrustes R2: 0.15, p value: 0.009). More recently, Hiremath et al. evaluated saliva samples from 26 children with EoE and 19 non-EoE age and ethnicity matched controls [39]. Their salivary microbiome was profiled using 16S rRNA gene sequencing and was compared to validated EoE disease activity indices. This study found consistent evidence that *Streptococcus* trended to be abundant in the oral microbiome, more specifically in children with active EoE compared with non-EoE controls (q value= 0.06). The relative abundance of *Haemophilus* was significantly higher in children with active EoE compared with inactive EoE (q value= 0.0008). Furthermore, when comparing the saliva samples from children with EoE to non-EoE controls, there was a trend toward lower alpha diversity and microbial richness in children with EoE (p<0.07).

Norder Grusell et al. evaluated the association between oral microbiome, EoE, and GERD [40]. They cultivated both brush samplings and mucosal punch biopsies from the oral cavity, and upper and lower esophagus from 17 subjects with GERD and 10 with EoE. The findings were compared to healthy control samples obtained from their previously published study using the same technique to survey the bacterial flora of the healthy human oral cavity, and the upper and lower esophagus [41]. They found that *als*-streptococci (*V*iridans streptococcus including species such as: *Streptococcus salivarius, Streptococcus mutans, Streptococcus mitis, Streptococcus sanguinis* and *Streptococcus anginosus*) was the most common group of bacteria in GERD, EoE, and healthy controls at all sample locations. No significant difference in species of the oral mucosa between EoE and healthy controls was seen. Overall, their results showed that GERD patients had less bacterial diversity in both oral and esophageal samples than EoE patients. Recently, Ziganshina et al. used 16S rRNA sequencing to investigate the complex nature of the salivary microbiota in patients with and without GERD [42]. They noted that the relative abundances of *Actinomyces* (estimated as 3.5% vs 2.5%), *Atopobium* (2.5% vs 1.5%), *Stomatobaculum* (0.7% vs 0.5%), *Ruminococcaceae [G-2] (0.3% vs 0.1%),* Veillonella* (9.5% vs 7.5%), and *Leptotrichia* (5.5% vs 2.5%) were significantly higher in the saliva samples of patients with GERD, while the *Porphyromonas* (6.0% vs 8.5%), *Gemella* (1.5% vs 2.0%), *Peptostreptococcus* (0.1% vs 0.2%), and *Neisseria* (4.0% vs 6.5%) were less abundant. There were no statistically significant differences in the diversity measured by Chao1, Shannon, and Simpson indices between the two study groups. Similarly, B. Wang et al. assessed the differences in the salivary bacterial community composition between patients with GERD and healthy controls [43]. Saliva samples from 55 patients with reflux esophagitis and 51 age-and sex-matched controls were analyzed via 16S rDNA gene sequencing. The abundances of *Prevotella, Veillonella, Megasphaera, Peptostreptococcus, Atopobium, Orribacterium, Eubacterium,* and *Lachnnaoradbaculum* were increased, while *Neisseria, Streptococcus, Rothia, Granulicatella, Gemella, Aggregatibacter, Treponema, Campylobacter, Filifactor, Corynebacterium,* and *Lactobacillus* were decreased in the reflux esophagitis patients compared to the controls. This study did not find a significant change in the diversity of oral microbiota in reflux esophagitis patients (Simpson index, p=0.60; Shannon index, p=0.38).

**Esophageal infections and dysmotility:**

While the association between oral candidiasis with candida esophagitis is a prime example of how oral microbiome dysbiosis can be intricately linked with an esophageal infection, we were unable to identify any publication examining this association. Similarly, no publications related to the association between the oral microbiome and infectious esophagitis (such as herpes simplex virus or cytomegalovirus infections) were identified. Furthermore, our search did not yield any publications describing the relationship between alterations in the oral microbiome and esophageal dysmotility (eg., achalasia, megaesophagus).

**DISCUSSION:**

In this narrative review, we summarized the evidence from studies describing the association between alterations in the oral microbiota and esophageal conditions. Even though this area of investigation is in its nascency, there is emerging evidence to suggest that oral microbiome is altered in esophageal diseases. Deciphering the role of oral microbiome in pathogenesis, diagnosis, prognosis, and management of esophageal conditions can have significant clinical implications.
Oral microbiome analysis is an innovative and evolving field, particularly with the biotechnological advancements. Initial studies examining the oral microbiome were based on culture-dependent methods such as controlling laboratory conditions or culture medium, microscopy, carbohydrate fermentation tests, and antibiotic susceptibility [44]. These approaches relied primarily on the phenotypic biochemical characterization. They required a high skill level for optimal results, and were time and resource intensive. Advances in the genomic techniques in 1980’s enabled culture-independent study of diverse microbial communities [45]. This led to a fundamental change in approaching and understanding the human microbiome including the oral microbiome [46–48]. The culture-independent approach has given rise to many exciting fields such as metagenomics, metatranscriptomics, metaproteomics, and single-cell genomics whose applications have provided abundant information on the functional dynamics of microbial environments.

Most of the studies summarized in this narrative review used culture independent methods, specifically 16S rRNA gene sequencing, to interrogate bacterial relative abundance and diversity in the clinical samples. The results suggest that the oral microbiome is unique for patients with esophageal malignancies, pre-malignancies, and benign conditions. Interestingly, the oral microbiome of patients with BE is dominated by gram-negative bacteria such as Fusobacterium, Prevotella, Dialister, Firmicutes, Lautropia, and Bacteroidales. As BE is one of the few known risk factors for esophageal cancer, the crosstalk between the oral microbiome and mechanism of pathogenesis of BE and subsequent esophageal adenocarcinoma remains an exciting area for translational research. Likewise, discovering the interplay between the oral microbiome and mechanisms underlying the development of other esophageal conditions also remains promising. It is conceivable that discerning the importance of these associations can help in developing a framework for cancer likelihood or diagnosis based on the microbial microenvironment.

Understanding the cause and effect relationship and how microbes are mechanistically linked to the pathogenesis of the several esophageal diseases is an area of active investigation. The previously reviewed studies proposed several mechanisms thought to encourage esophageal conditions. One proposed mechanism is direct adhesion and subsequent invasion by the bacterium, which ultimately induces inflammation and alters the host immunity thereby encouraging the transition to dysplasia and ultimately promoting carcinogenesis [26, 27]. Additional possibilities include induction of a pro-inflammatory group of bacteria after loss of certain microbiomes leading to proliferation of other bacteria capable of opportunistic pathogenicity (such as Clostridium in the case of the colon) [35], or as a result of a direct interaction with the nutrients and esophageal binding sites [49]. Others suggest that diet plays a role and specifically food allergen mediated eosinophilia may drive inflammation in the esophagus and may be linked to esophageal disease [29, 30, 37, 39]. Though the current studies show associations between various microbes and esophageal diseases, no distinct pathogenetic mechanisms have been identified for these microbiome alterations.

Despite the promise, it is important to note that a direct comparison and analysis of the results among these studies can be challenging because of the variability in sample collection (mouthwash samples vs saliva), the cross-sectional nature of the studies, and heterogeneity in their study design. Much of the research to date has focused on perturbations of the oral microbiome in esophageal cancerous, precancerous, and benign diseases. There is paucity of data related to oral microbiome and infectious esophageal conditions and esophageal motility disorders. Furthermore, there is epidemiological data to suggest that environmental factors and local factors can alter the oral microbiome. While most of the studies excluded individuals with periodontal/gingival diseases, there was no clear indication of how they addressed the confounding effects of many of the other variables. While the 16S rRNA sequencing remains the standard for bacterial taxonomic profiling at this time, it falls short in its ability to characterize viruses and fungi, bacteria at the species level, and it does not directly evaluate function or the interplay between the host and the microbe. Metagenomics and metatranscriptomics holds potential to give information not only about the microbial composition at the species level, but it also can also provide insight into involved metabolic pathways [50]. This can be valuable in assessing the causality, promoting novel diagnostic approaches, and developing a personal and precise approach wherein clinicians can alter oral microbiome using drug development and targeted therapy to improve clinical outcomes. Furthermore, additional studies are needed to determine whether alterations in the microbiome can impact the natural history of various esophageal diseases.
CONCLUSION:
We reviewed the current evidence available for alterations in oral microbiome in esophageal diseases. Emerging data suggests that there are distinct oral microbiome patterns associated with malignant, pre-malignant, and benign esophageal conditions. Further studies are needed to determine the causal relationship between oral microbiome and malignant, pre-malignant, and benign esophageal diseases. There is an opportunity for further research to discern the oral microbiome composition in esophageal infections and esophageal dysmotility conditions.

Statements
Conflict of Interest Statement: The authors have no conflicts of interest to declare.

Funding Sources:
R.B. is supported by T32 training grant (5T32HD060554-10), the Thrasher Research Fund, and the Vanderbilt Institute for Clinical and Translational Research (VICTR). SRD is currently supported by NIAID (R21AI147281, R21AI147282, R21AI147283-01A1S3, U19AI095227 and P30AI110277), NHLBI (1R01HL146401), and start-up funds from Vanderbilt University Medical Center. G.H. is supported by the American College of Gastroenterology Junior Faculty Development Award, and the Eunice Kennedy Shriver National Institute of Child Health & Human Development of the National Institutes of Health (NIH) under the Award Number K12HD087023.

Author Contributions
Rachel Bernard: Contributed towards literature search, identifying relevant publications, data extraction, interpreting the results, drafted the manuscript and designed the Tables and Figures.
Irtiqa Fazili: Contributed towards literature search, identifying relevant publications, data extraction, interpreting the results, drafting the manuscript and designed the Tables.
Seesandra V. Rajagopala: Contributed towards conceiving and designing the study, identifying relevant publications, data extraction, interpreting the results, and made critical contributions in the manuscript.
Suman R. Das: Contributed towards conceiving and designing the study, data extraction, interpreting the results, and made critical contributions in the manuscript.
Girish Hiremath: Contributed towards conceiving and designing the study, literature search, identifying relevant publications, data extraction, interpreting the results, drafted the manuscript, and designing the Tables and Figures.
All authors have given final approval of the version to be published.

REFERENCES


Legends:
Figure 1: Schematic illustration of the literature search
Figure 2: Summary of changes in the oral microbiome in various esophageal diseases
Records identified through database searching (n=46)

Titles/Abstracts screened (n=46) → Irrelevant records excluded by title and abstract review (n=28)

Full articles assessed for eligibility (n=18) → Full articles excluded: No relevant outcome (n=2)

Studies included in qualitative synthesis (n=16)
### Table 1: Summary of Studies Applying Oral Microbiome Analysis in Esophageal Diseases

<table>
<thead>
<tr>
<th>Condition</th>
<th>Author Year (Ref)</th>
<th>Methods</th>
<th>Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Esophageal Carcinoma</td>
<td>Narikiyo 2004 (26)</td>
<td>• Sample size: not provided&lt;br&gt;• Saliva samples from patients with esophageal carcinoma and healthy controls&lt;br&gt;• 16S rRNA gene PCR amplicons were cloned into a shuttle vector, then one hundred clones were sequenced</td>
<td>• Higher abundance: <em>Treponema denticola</em> and <em>Streptococcus anginosus</em></td>
</tr>
<tr>
<td>Esophageal Carcinoma</td>
<td>Kageyama 2019 (27)</td>
<td>• Sample size: n=24&lt;br&gt;• Saliva samples from 59 DTC patients (n=12 with esophageal cancer) and 118 age/sex matched controls&lt;br&gt;• 16S rRNA gene sequencing (V1 to V2 region)</td>
<td>• Higher abundance: <em>Porphyromonas gingivalis</em>, <em>Corynebacterium</em> species, and <em>Fusobacterium nucleatum subspecies vincentii</em>&lt;br&gt;• Diversity: increased</td>
</tr>
<tr>
<td>Esophageal Carcinoma</td>
<td>Zhao 2020 (28)</td>
<td>• Sample size: n=90&lt;br&gt;• Mouth rinses from 39 esophageal carcinoma patients and 51 healthy controls&lt;br&gt;• 16S rRNA gene sequencing (V3 to V4 region)</td>
<td>• Higher abundance: <em>Firmicutes</em>, <em>Negativicutes</em>, <em>Selenomonadales</em>, <em>Prevotellaceae</em>, <em>Prevotella</em>, and <em>Veillonellaceae</em> taxa&lt;br&gt;• Lower abundance: <em>Proteobacteria</em>, <em>Betaproteobacterita</em>, <em>Neisseriales</em>, <em>Neisseriaceae</em>, and <em>Neisseria</em>&lt;br&gt;• Diversity: no significant difference</td>
</tr>
<tr>
<td>ESCC</td>
<td>X. Chen 2015 (29)</td>
<td>• Sample size: n=235&lt;br&gt;• Saliva samples from 87 ESCC cases, 63 dysplastic cases, and 85 healthy controls&lt;br&gt;• 16S rRNA gene sequencing (V3 to V4 region)</td>
<td>• Higher abundance: <em>Streptococcus</em>, <em>Prevotella</em>, and <em>Porphyromonas</em>&lt;br&gt;• Lower abundance: <em>Lautropia</em>, <em>Bulleidia</em>, <em>Catonella</em>, <em>Corynebacterium</em>, <em>Moryella</em>, <em>Peptococcus</em> and <em>Cardiobacterium</em>&lt;br&gt;• Diversity: decreased</td>
</tr>
<tr>
<td>ESCC</td>
<td>Q. Wang 2019 (30)</td>
<td>• Sample size: n=41&lt;br&gt;• Saliva samples from 20 ESCC and 21 healthy controls&lt;br&gt;• 16S rRNA gene sequencing (V3 to V4 region)</td>
<td>• Higher abundance: <em>Firmicutes</em>, <em>Bacillus</em>, and <em>Lactobacillus</em>&lt;br&gt;• Lower abundance: <em>Gammaproteobacteria</em>&lt;br&gt;• Diversity: no significant difference</td>
</tr>
<tr>
<td>ESCC</td>
<td>Meng 2019 (32)</td>
<td>• Sample size: n=52&lt;br&gt;• Saliva samples from 30 ESCC and 22 healthy controls&lt;br&gt;• 16S rRNA gene sequencing (V4)</td>
<td>• Higher abundance: <em>Porphyromonas</em>, <em>Streptococcus</em>, and <em>Leptotrichia</em></td>
</tr>
<tr>
<td>ESCC</td>
<td>M.F. Chen 2020 (31)</td>
<td>• Sample size: n=52&lt;br&gt;• Oral biofilms from 34 ESCC and 18 healthy controls&lt;br&gt;• 16S rRNA gene sequencing (V3-V4)</td>
<td>• Higher abundance: <em>Streptococcus</em> species, <em>Veillonella parvula</em>, and <em>P. gingivalis</em>&lt;br&gt;• Diversity: significantly different</td>
</tr>
<tr>
<td>Study</td>
<td>Authors</td>
<td>Year</td>
<td>Sample size</td>
</tr>
<tr>
<td>----------------</td>
<td>--------------</td>
<td>------</td>
<td>-------------</td>
</tr>
<tr>
<td>ESCC/EAC</td>
<td>Peters</td>
<td>2017</td>
<td>n=316</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ESCC/EAC</td>
<td>Kawasaki</td>
<td>2021</td>
<td>n=123</td>
</tr>
<tr>
<td>BE</td>
<td>Snider</td>
<td>2018</td>
<td>n=49</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BE</td>
<td>Okereke</td>
<td>2019</td>
<td>n=17</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EoE</td>
<td>Benitez</td>
<td>2015</td>
<td>n=68</td>
</tr>
<tr>
<td>EoE</td>
<td>Hiremath</td>
<td>2019</td>
<td>n=35</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GERD and EoE</td>
<td>Norder Grussell</td>
<td>2018</td>
<td>n=27</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| GERD | Ziganshina 2020 (42) | Sample size: n=26  
Saliva samples from 12 GERD and 14 controls  
16S rRNA gene sequencing (V3-V4 region) | Higher abundance: Actinomyces, Atopobium, Stomatobaculum, Ruminococcaceae_[G-2], Veillonella, and Leptotrichia in GERD  
Lower abundance: Porphyromonas, Gemella, Peptostreptococcus, and Neisseria  
Diversity: no significant difference |
|---|---|---|---|
| GERD | B. Wang 2020 (43) | Sample size: n=106  
Saliva samples from 55 reflux esophagitis and 51 controls  
16S rDNA gene sequencing (V3-V4 region) | Higher abundance: Prevotella, Veillonella, Megasphaera, Peptostreptococcus, Atopobium, Oribacterium, Eubacterium, and Lachnoanaerobaculum  
Lower Abundance: Neisseria, Streptococcus, Rothia, Granulicatella, Gemella, Aggregatibacter, Treponema, Campylobacter, Filifactor, Corynebacterium, and Lacticibrio  
Diversity: no significant difference |

**ESCC**= esophageal squamous cell carcinoma, **EAC**= esophageal adenocarcinoma, **DTC**= digestive tract cancers, **BE**= Barrett’s esophagus, **EoE**= eosinophilic esophagitis, **GERD**= gastroesophageal reflux disease